All In Biotech

Drug Trial Radar · NCT05587894

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial: the OPTICOV Study

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

256

Planned (sponsor's estimate)

Start

Apr 27, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Oct 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.

Conditions

  • COVID-19
  • Immunodeficiency

Interventions

  • Paxlovid 5 daysDrug

    Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

  • Paxlovid 10 daysDrug

    Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.

  • VekluryDrug

    Remdesivir "flash", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with SARS-CoV-2 viral load (threshold cicle (Ct) <32) by real-time RT-PCR in nasopharyngeal swabs at Day 10 after treatment initiation.Time frame: Day 10

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • Saint-André Hospital

    Bordeaux, Bordeaux, France · Recruiting

  • Pellegrin Hospital

    Bordeaux, Bordeaux, France · Recruiting

  • Francois Mitterrand Hospital

    Dijon, Dijon, France · Recruiting

  • Croix Rousse Hospital

    Lyon, Lyon, France · Recruiting

  • La Colombière Hospital

    Montpellier, Montpellier, France · Recruiting

  • Hotel Dieu Hospital

    Nantes, Nantes, France · Recruiting

  • Laribosière Hospital

    Paris, Paris, France · Recruiting

  • Saint Antoine Hospital

    Paris, Paris, France · Recruiting

  • Pitié-Salpêtrière Hospital

    Paris, Paris, France · Recruiting

  • Saint Louis Hospital

    Paris, Paris, France · Recruiting

  • Bichat Claude-Bernard Hospital

    Paris, Paris, France · Recruiting

  • Robert Debré Hospital

    Reims, Reims, France · Recruiting

  • Purpan Hospital

    Toulouse, Toulouse, France · Recruiting

  • Tourcoing Hospital

    Tourcoing, Tourcoing, France · Recruiting

  • Division of Infectious Diseases, Verona University Hospital

    Verona, Italy · Recruiting

  • Drammen Hospital, Vestre Viken Hospital

    Drammen, Norway · Recruiting

  • Oslo University Hospital and University of Oslo

    Oslo, Norway · Recruiting

  • Vestfold Hospital Trust

    Tønsberg, Norway · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.